Loading
THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.
THEO-260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Theolytics Limited, in ovarian cancer. An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system.
1.THEO-260 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"THEO-260" OR ABSTRACT:"THEO-260") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about THEO-260, not a curated reading list.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.